Innate Pharma SA (IPHA) — 20-F Filings
All 20-F filings from Innate Pharma SA. Browse 1 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (1)
-
Innate Pharma Faces High R&D Uncertainty, Relies on Partnerships
— Apr 1, 2026 Risk: high
Innate Pharma SA (IPHA) filed its 20-F for the fiscal year ended December 31, 2025, highlighting its status as a clinical-stage oncology-focused biotech company
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX